Design of febuxostat-meglumine multi-system through screening method
발표자
()
초록
내용
Since most of drugs have low solubility, many pharmaceutical companies and research institutes invest a lot of time, effort, and fund to improve the solubility of poorly soluble drugs. The model drug, febuxostat (Febux), is a novel bipurin-selective xanthine oxidase inhibitor marketed as Uloric® in BCS Class II drugs. The purpose of study is to improve the in vitro dissolution (%) of Febux using a screening method on solid dispersion (SD). The novel Febux SD formulation (Febux:meglumine:P407:mannitol = 1:2:1:1) has been successfully developed. The dissolution (%) of Febux of optimal formulation (SD3) in pH 1.2, distilled water (DW), and pH 6.8 buffer were 6.3-, 2.6-, and 1.1-times higher than that of Feburic® tab (commercial product), respectively, at 60 min. Moreover, the SD3 formulation was secured the stability for 6 months. In conclusion, the Febux multi-system using a meglumine was successfully prepared for the first time.